

1 **Phosphorous pentoxide-free bioactive glass exhibits**
2 **dose-dependent angiogenic and osteogenic capacities**
3 **which are retained in glass polymeric composite**
4 **scaffolds†**

5
6 Sonia Font Tellado,^a José Angel Delgado,^{b,c} Su Ping Patrino Poh,^{a,d} Wen
7 Zhang,^{e,f} Maite García-Vallés,^g Salvador Martínez,^g Alejandro Gorustovich,^h
8 Lizette Morejón,^b Martijn van Griensven^{a,i} and Elizabeth Rosado
9 Balmayor^{*a,j}

10
11 ^a Experimental Trauma Surgery, Klinikum rechts der Isar, Technical University of Munich,
12 81675 Munich, Germany

13 ^b Center for Biomaterials, University of Havana, 10400 Havana, Cuba

14 ^c Universitat Internacional de Catalunya, 08195 Barcelona, Spain

15 ^d Berlin Institute of Health at Charité – Universitätsmedizin Berlin, Julius Wolff Institute, 13353
16 Berlin, Germany

17 ^e Institute of Molecular Immunology and Experimental Oncology, Klinikum rechts der Isar,
18 Technical University of Munich, 81675 Munich, Germany

19 ^f Ethris GmbH, 82152 Planegg, Germany

20 ^g Mineralogy, Petrology and Applied Geology Department, University of Barcelona, 08028
21 Barcelona, Spain

22 ^h Interdisciplinary Materials Group-IESIING-UCASAL, INTECIN UBA-CONICET, A4400EDD Salta,
23 Argentina

24 ⁱ cBITE, MERLN Institute for Technology-Inspired Regenerative Medicine, Maastricht
25 University, 6200 MD Maastricht, the Netherlands

26 ^j BE, MERLN Institute for Technology-Inspired Regenerative Medicine, Maastricht
27 University, 6200 MD Maastricht, the Netherlands.

28
29 E-mail: e.rosadobalmayor@maastrichtuniversity.nl
30

31 **Abstract**

32 Bioactive glasses (BGs) are attractive materials for bone tissue engineering because
33 of their bioactivity and osteoinductivity. In this study, we report the synthesis of a novel
34 phosphorous pentoxide-free, silicate- based bioactive glass (52S-BG) composed of 52.1%
35 SiO₂, 23.2% Na₂O and 22.6% CaO (wt%). The glass was thoroughly characterized. The
36 biocompatibility and osteogenic properties of 52S-BG particles were analyzed in vitro with
37 human adipose-derived mesenchymal stem cells (AdMSCs) and human osteoblasts. 52S-BG
38 particles were biocompatible and induced mineralized matrix deposition and the expression
39 of osteogenic markers (RunX2, alkaline phosphatase, osteocalcin, osteopontin, collagen I)
40 and the angio- genic marker vascular endothelial growth factor (VEGF). Angiogenic
41 properties were additionally confirmed in a zebrafish embryo model. 52S-BG was added to
42 poly-ε-caprolactone (PCL) to obtain a composite with 10 wt% glass content. Composite
43 PCL/52S-BG scaffolds were fabricated by additive manufacturing and displayed high
44 porosity (76%) and pore interconnectivity. The incorporation of 52S-BG particles increased
45 the Young's modulus of PCL scaffolds from 180 to 230 MPa. AdMSC seeding efficiency
46 and proliferation were higher in PCL/52S-BG compared to PCL scaffolds, indicating
47 improved biocompatibility. Finally, 52S-BG incorporation improved the scaffolds'
48 osteogenic and angiogenic properties by increasing mineral deposition and inducing relevant
49 gene expression and VEGF protein secretion. Overall, 52S-BG particles and PCL/52S-BG
50 composites may be attractive for diverse bone engineering applications requiring
51 concomitant angiogenic properties.

52

53 **1. Introduction**

54 To date, a wide variety of biomaterials have been applied in bone tissue engineering.
55 Among these, bioactive glasses (BGs) are particularly attractive because of their potential to
56 induce bone formation (osteoinductivity) and ability to form a hydroxycarbonate apatite
57 layer on the glass surface when exposed to biological fluids (bioactivity).¹

58 Since the commercialization of 45S5 Bioglass® (45% SiO₂, 24.5% Na₂O, 24.5%
59 CaO and 6% P₂O₅ in wt%) in 1969,² a variety of BGs have been synthesized for bone
60 regeneration. Commonly, silicon dioxide (SiO₂), boron trioxide (B₂O₃) and/or phosphorous
61 (P) form the main glass network, while elements such as sodium (Na), calcium (Ca),
62 magnesium (Mg), strontium, (Sr) and also P can act as network modifiers, influencing the
63 degree of solubility and the release of ionic products from BGs.³ A large proportion of the
64 currently available BGs are composed of silicon (Si) and P. It has been extensively reported
65 that Si is essential for bone tissue formation and its calcification,⁴ while P plays a role in

66 stimulating matrix Gla protein expression, a key regulator in bone formation.⁵ Interestingly,
67 the role of phosphorous pentoxide (P₂O₅) remains strongly debated. P₂O₅-free BGs, that is,
68 from the groups SiO₂-CaO and SiO₂-CaO-Na₂O have shown to be highly advantageous.⁶⁻
69 ⁸ These BGs have been shown to be bioactive^{6,9,10} and capable of inducing extracellular
70 matrix (ECM) secretion and mineralization by primary human osteoblasts (OBs).⁷ In
71 addition, P₂O₅-free BG may be particularly useful to some fabrication techniques.⁷
72 Scaffolds with adequate mechanical properties and interconnected porosity have been
73 produced using P₂O₅- free BG by foaming process techniques.⁷ Overall, this suggests that
74 P₂O₅-free BGs feature unique advantages while maintaining osteogenic properties.
75 Furthermore, the presence of P₂O₅ has been associated with a tendency for easy
76 hydrolysis.¹¹ Therefore, P₂O₅ BGs may be more suitable as temporary implants, highly
77 attractive for soft tissue, rather than bone tissue engineering.¹¹

78 Several studies have demonstrated that cell behavior, in particular osteogenesis, can
79 be altered by the dissolution products of BGs (reviewed in ref. 3). Most investigation has
80 been restricted to cell lines, resulting in the current lack of evidence in clinically relevant
81 cells. Moreover, to date, there are limited studies which provide a direct comparison of the
82 effects of BGs on different cell types relevant for bone tissue engineering, including human-
83 derived mesenchymal stem cells and human OBs. Furthermore, most evidence on the
84 angiogenic properties of these materials is described for Cu²⁺ and Co²⁺ doped glasses^{12,13}
85 or for boron-containing glasses.¹⁴ Concerns exist regarding cellular toxicity of Co²⁺ doped
86 BGs.^{15,16} Despite their clear advantages, little evidence is available regarding the
87 angiogenic properties of P₂O₅-free BGs.

88 The adoption of BGs for the regeneration of living bone in large volumes, load-
89 bearing defects has been limited because of their inherent brittleness and low fracture
90 toughness.¹⁷ A good alternative is to use composite scaffolds to harness and combine the
91 advantages of different biomaterials into a single component.¹⁸ BGs are attractive additives

92 that can be added to polymeric scaffolds to enhance the bioactivity of the final composite
93 biomaterial.

94 In the present study, a novel P₂O₅-free BG containing 52.1% SiO₂, 23.2% Na₂O and
95 22.6% CaO (wt%) was synthesized (termed 52S-BG hereafter). The dose-dependent
96 biocompatibility and osteogenic and angiogenic potential of 52S-BG particles on human
97 adipose-derived mesenchymal stromal cells (AdMSCs) and OBs were evaluated. In addition,
98 the angiogenic potential of the 52S-BG particles was further investigated in vivo in a
99 zebrafish embryo model. Subsequently, composite scaffolds comprising PCL and 10 wt%
100 52S-BG particles were fabricated by melt-extrusion-based additive manufacturing. PCL is a
101 biodegradable synthetic polymer with good rheological and viscoelastic properties that has
102 been approved by the FDA in several biomedical devices.^{19,20} PCL is particularly attractive
103 for tissue engineering. Its low melting temperature readily allows the fabrication of three-
104 dimensional (3D) scaffolds using this polymer by various processing tech- niques.²¹
105 However, PCL is hydrophobic and features poor bioactivity. We hypothesized that by
106 fabricating a PCL/52S-BG composite scaffold, crucial features for tissue engineering would
107 be gained. Therefore, the ability of PCL/52S-BG compo- site scaffolds to retain the
108 bioactivity and osteogenic and angiogenic potential initially displayed by the 52S-BG
109 particles was evaluated in vitro in AdMSCs.

110

111 **2. Experimental**

112 2.1. 52S-BG particles

113 2.1.1. Precursor materials: silica sand and calcite mineral. The silica sand used as
114 raw material for the synthesis of the glass was extracted from the Santa Teresa silica sand
115 deposit. This deposit is located in the southwest of Pinar del Rio province in Cuba; it is of
116 alluvial origin and is characterized by quartzose sands. The silica sand used contained 99.2
117 wt% SiO₂.²² The calcite mineral used during the glass synthesis was extracted from the
118 Jaruco deposit in Mayabeque province in Cuba. The calcite mineral was composed of 57.62
119 ± 0.07 wt% CaO, 0.269 ± 0.005 wt% MgO, 0.25 ± 0.09 wt% SiO₂ and trace elements.²²
120 Further characterization of the raw materials can be found elsewhere.²² Prior to use, both
121 materials were sieved and manually ground using an agate mortar.

122 2.1.3. Precursor materials: silica sand and calcite mineral. The silica sand used as
123 raw material for the synthesis of the glass was extracted from the Santa Teresa silica sand
124 deposit. This deposit is located in the southwest of Pinar del Rio province in Cuba; it is of
125 alluvial origin and is characterized by quartzose sands. The silica sand used contained 99.2
126 wt% SiO₂.²² The calcite mineral used during the glass synthesis was extracted from the
127 Jaruco deposit in Mayabeque province in Cuba. The calcite mineral was composed of 57.62
128 ± 0.07 wt% CaO, 0.269 ± 0.005 wt% MgO, 0.25 ± 0.09 wt% SiO₂ and trace elements.²²
129 Further characterization of the raw materials can be found elsewhere.²² Prior to use, both
130 materials were sieved and manually ground using an agate mortar.

131 Precursor materials: silica sand and calcite mineral. The silica sand used as raw
132 material for the synthesis of the glass was extracted from the Santa Teresa silica sand deposit.
133 This deposit is located in the southwest of Pinar del Rio province in Cuba; it is of alluvial
134 origin and is characterized by quartzose sands. The silica sand used contained 99.2 wt%
135 SiO₂.²² The calcite mineral used during the glass synthesis was extracted from the Jaruco
136 deposit in Mayabeque province in Cuba. The calcite mineral was composed of 57.62 ± 0.07
137 wt% CaO, 0.269 ± 0.005 wt% MgO, 0.25 ± 0.09 wt% SiO₂ and trace elements.²² Further
138 characterization of the raw materials can be found elsewhere.²² Prior to use, both materials
139 were sieved and manually ground using an agate mortar.

140 2.1.3. 52S-BG characterization. The elemental composition of synthesized 52S-BG
141 was analyzed by X-ray fluorescence using a PW 2400 photometer (Philips, Cambridge, MA,
142 USA) with two excitation sources, a rhodium anode and a golden anode. Identification of
143 the glass crystalline phases was performed by X-ray diffraction (XRD) using a D5000
144 diffractometer (Siemens AG, Berlin, Germany) with CuK α radiation ($\lambda = 1.5484 \text{ \AA}$) in the
145 interval of 10–70° and an incident angle of 0.05°. Thermal analysis of the glass was
146 performed using a NETZSCH STA 409 simultaneous thermogravimetric and differential
147 thermal analyzer (TG-DTA, Netzsch GmbH, Selb, Germany). Aluminum oxide (Al₂O₃) in
148 a static air atmosphere and a heating speed of 5 °C min⁻¹ was used as a reference material.

149 2.2. Fabrication of PCL and PCL/52S-BG scaffolds by additive manufacturing

150 52S-BG particles were incorporated into the PCL bulk. Briefly, 10% (w/v) PCL
151 solution was prepared by dissolving 10 g PCL pellets (CAPA 6500, Perstorp Ltd,
152 Warrington, United Kingdom) in 100 ml chloroform (MERCK Millipore, Melbourne,

153 Australia) at room temperature. Subsequently, 10 wt% 52S-BG particles (relative to the PCL
154 mass) were added to the PCL solution and stirred to obtain a homogenous mixture. Given
155 the small size of the 52S-BG particles, 10 wt% was selected to prevent particle
156 agglomeration that may compromise the scaffold mechanical properties.^{24,25} The
157 PCL/52S-BG solution was precipitated into 5-fold excess ethanol (absolute, MERCK
158 Millipore). The solid PCL/52S-BG composite was isolated and air-dried to evaporate the
159 solvent. Finally, PCL and PCL/52S-BG scaffolds were fabricated using an in-house melt
160 extrusion-based 3D printer at 90 °C and 100 °C, respectively.¹⁹ All scaffolds were fabricated
161 using a 21G nozzle with a lay-down pattern of 0–90°, filament gap of 1 mm and layer
162 thickness of 0.4 mm. Scaffolds of 30 mm length (L) × 30 mm width (W) × 3 mm height (H)
163 were fabricated.

164 For cell culture, mechanical testing and degradation experiments, PCL and PCL/52S-
165 BG scaffolds were cut in 4 mm (L) × 4 mm (W) × 3 mm (H) pieces. Subsequently, all
166 scaffolds were immersed in 70% ethanol for 30 min under vacuum and treated with 5 M
167 sodium hydroxide for 90 min at 37 °C to increase surface roughness and expose
168 the 52S-BG particles.^{19,26} Disinfection prior to cell culture was performed by
169 treatment with 70% ethanol for 30 min.

170 2.3. Characterization of PCL and PCL/52S-BG scaffolds

171 Scaffold morphology, porosity, pore size distribution, filament thickness and 52S-
172 BG particle content were analyzed by micro-computed tomography (Skyscan 1176, Bruker,
173 Kontich, Belgium) at a voxel size of 9 μm (n = 6 for each scaffold type). Image
174 reconstruction was performed using the Skyscan CTRecon software and image analysis was
175 performed with the Skyscan CTAn software using a built-in algorithm.

176 Degradation and water uptake were analyzed in eight scaffolds of each type. For these
177 experiments, the initial weight of each scaffold was recorded. Subsequently, each scaffold
178 was placed in a 15 ml conical tube (Greiner Bio-One GmbH, Frickenhausen, Germany) and
179 incubated at 37 °C with 3 ml phosphate-buffered saline (PBS) solution for 2 or 4 weeks.
180 After each time point, the scaffolds were collected from the PBS and weighted twice, (i)
181 immediately after removing the excess PBS and (ii) 48 h after vacuum-drying (final, constant
182 weight). Water uptake and weight loss were calculated using previously reported
183 equations.²⁷

184 The mechanical properties of the PCL and PCL/52S-BG scaffolds (n = 8 for each
185 type of scaffold) were tested by subjecting the scaffolds to 10% compression using a
186 zwickLine 1120 microtester (ZwickRoell GmbH, Ulm, Germany) fitted with a 2.5 kN load
187 cell at a rate of 1 mm min⁻¹. Young's modulus was calculated from the stress-strain curve
188 at values between 3–8% strain. The area of the scaffolds was calculated as (L) × (H) × (100
189 – % porosity). Scaffolds were tested before and after 2 or 4 weeks of degradation in PBS.

190 2.4. Ion release from 52S-BG particles and PCL/52S-BG scaffolds

191 52S-BG particles (concentrations of 100, 200, 300, 400 and 1000 µg ml⁻¹) and PCL
192 and PCL/52S-BG scaffolds were incubated with non-supplemented low glucose Dulbecco's
193 Modified Eagle's Medium (DMEM) at 37 °C. The pH was measured using a WTW inoLab
194 720 pH meter (Gemini B.V., Apeldoorn, the Netherlands) immediately and after 3 or 7 days
195 of incubation. The cumulative release of Si, Na, Ca and P ions was analyzed by inductively
196 coupled plasma optical emission spectrometry (ICP-OES, Optima 8300, PerkinElmer,
197 Waltham, MA, USA). ICP-OES measurements were performed on the supernatants
198 collected at 3, 6 and 12 h and 1, 5 and 7 days after incubation. The data of ionic concentration
199 was normalized to the DMEM ionic concentration that was measured as baseline control at
200 each time-point.

201 2.5. Cell isolation and expansion

202 Tissue collection for cell isolation was approved by the local ethical committee of
203 the "Klinikum rechts der Isar" at the Technical University of Munich (Munich, Germany).
204 Tissue collection was performed after obtaining the patient's written informed consent and
205 in accordance with the most recent guidelines of the declaration of Helsinki. Six healthy
206 human donors were enrolled in this study. Adipose tissue from subcutaneous fat (n = 3) was
207 used for AdMSCs while bone tissue from femoral heads (n = 3) was collected for OBs
208 isolation.

209 AdMSCs were isolated following the protocol described in.²⁸ Briefly, fat tissue was
210 cut into small pieces (0.5–2 mm), washed twice in PBS and centrifuged (5810R, Eppendorf
211 AG, Hamburg, Germany) at 600g for 10 min. Subsequently, the tissue was digested with
212 1.45% collagenase solution (Biochrom GmbH, Berlin, Germany) for 30 min at 37 °C and
213 centrifuged at 600g for 10 min to obtain a cell pellet. Cells were cultured and expanded on
214 175 cm² flasks (Eppendorf AG) using AdMSC expansion medium (i.e. high glucose DMEM
215 supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin (P/S)) at

216 37 °C under 5% CO₂. The culture medium was changed 24 h after isolation and twice a
217 week during expansion.

218 OBs were isolated following the protocol described in ref. 29. In brief, cancellous
219 bone was cracked in small pieces (1–4 mm) and washed twice with PBS. Subsequently, bone
220 pieces were transferred to 175 cm² flasks (Eppendorf AG) and cultured in OB expansion
221 medium (i.e. low glucose DMEM supplemented with 10% FBS, 1% P/S and 0.2 M L-
222 ascorbate-2- phosphate) at 37 °C under 5% CO₂. The cell culture medium was changed
223 twice a week, passaging the cells once 80% con- fluence was reached.

224 2.6. Cell culture with 52S-BG particles

225 AdMSCs or OBs were seeded on tissue culture plates (TPP Techno Plastic Products
226 AG, Trasadingen, Switzerland) at a density of 2.1×10^4 cells per cm². Subsequently, both
227 cell types were independently cultured in the presence of different 52S-BG particle
228 concentrations (direct contact with the particles; 100–1000 µg ml⁻¹, Table 1).

229 For cytotoxicity and cell proliferation assays, expansion medium was used according
230 the cell type investigated. For ALP activity, mineralization and gene/protein expression
231 assays, cells were cultured under serum starvation conditions (i.e. low glucose DMEM + 2%
232 FBS + 1% P/S) to support in vitro cellular differentiation. Low serum conditions have been
233 correlated with a better maintenance of MSCs pluripotent phenotype³⁰ as well as their
234 superior angiogenic³¹ and osteogenic differentiation.³² A plausible explanation for this may
235 be related to the low serum levels present at poorly vascularized injuries and bone fracture
236 sites. Therefore, low serum conditions may be more accurately mimicking the bone fracture
237 microenvironment. Additionally, serum starvation medium was supplemented with 10 mM
238 β-glycerophosphate (AppliChem GmbH, Darmstadt, Germany) and 0.2 M L-ascorbate-2-
239 phosphate to support in vitro matrix deposition.³³ An overview of the setup of the cell
240 culture experiments used during the 52S-BG particles evaluation is presented in Table 1.
241 Medium change was performed twice a week.

242 2.7. Cell culture on PCL and PCL/52S-BG scaffolds

243 AdMSCs were seeded on PCL and PCL/52S-BG scaffolds at a density of 2×10^4
244 cells per scaffold. In samples for gene and protein expression experiments, cell density was
245 increased to 2×10^5 cells per scaffold to obtain enough cellular material for these assays.

246 Scaffolds were placed in 48-well plates and seeded by using 30 μ l cell suspension per
247 scaffold. After 1.5 h of incubation at 37 °C under 5% CO₂, fresh culture medium was added
248 to reach a final volume of 1 ml. Culture was performed at 37 °C under 5% CO₂ (further
249 details are listed in Table 1). Medium was changed twice a week.

250 2.8. Biocompatibility of 52S-BG particles and PCL/52S-BG scaffolds: cell viability and
251 proliferation

252 Live/dead staining was performed of AdMSCs and OBs after separate culture with
253 52S-BG particles. In addition, AdMSCs cultured on PCL or PCL/52S-BG scaffolds were
254 also evaluated. The times of observation selected were 1, 3 and 7 days after culture (for both,
255 particles and scaffolds). For this experiment, samples were washed with PBS and incubated
256 for 15 min at 37 °C with a solution containing 0.05% calcein AM, 0.2% propidium iodide
257 and 0.01% Hoechst (all solutions prepared in sterile PBS). Images were obtained using a B7-
258 9000 fluorescence microscope (Keyence, Osaka, Japan) and processed using the BZ-II
259 Analyzer software.

260 For cytotoxicity, the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
261 bromide) assay was performed to evaluate both particles and scaffolds, while the lactate
262 dehydrogenase (LDH) assay was additionally performed for the scaffolds.

263 2.8.1. MTT assay. Following the selected times of observation of 1, 3 or 7 days after
264 culture, samples were washed with PBS and incubated in MTT solution (1.2 mM in PBS,
265 Carl Roth GmbH, Karlsruhe, Germany) for 1.5 h at 37 °C. Subsequently, samples were
266 incubated for either 10 min (AdMSCs or OBs cultured with 52S-BG particles) or 30 min
267 (AdMSCs cultured on PCL or PCL/52S-BG scaffolds) in a solution containing 10% sodium
268 dodecyl sulfate and 0.6% acetic acid in dimethyl sulfoxide (Carl Roth GmbH) at room
269 temperature. Absorbance at 570 nm and 690 nm was determined using a FLUOstar Omega
270 plate reader photometer (Labtech, Ortenberg, Germany). Latex rubber was used to induce
271 cell death (MTT positive control).³⁴ Untreated cells were used as 100% cell viability (MTT
272 negative control). With the scaffolds, the results were reported as optical density from
273 PCL/52S-BG scaffolds compared to PCL scaffolds used as the control.

274 2.8.2. LDH assay. This assay was performed to evaluate the activity of LDH, a
275 stable cytoplasmic enzyme, in the cell culture supernatants after culture of AdMSCs on the
276 PCL/ 52S-BG scaffolds. This enzyme is only released to the extra-cellular environment by
277 damaged cells.³⁵ For LDH determination, AdMSCs were cultured on PCL/52S-BG

278 scaffolds for 1, 3 or 7 days. Similar to the MTT assay, PCL scaffolds were used as the control.
279 The assay was conducted by means of a Fluitest LDH-L kit (Analyticon Biotechnologies
280 AG, Lichtenfels, Germany) following the manufacturer's instructions. Briefly, at the
281 predetermined observation times, 100 μ L cell culture supernatant were transferred in
282 triplicate to a 96-well plate and 100 μ L LDH working solution were applied on top. Rapidly
283 after addition, absorbance was determined at 340 nm using the plate reader. The LDH
284 concentration was calculated by means of a calibration curve using an LDH standard
285 provided in the Fluitest LDH-L kit.

286 2.8.3. DNA quantification assay. Cell proliferation was evaluated by means of the
287 total DNA amount, as determined using a Quant-iT™ PicoGreen dsDNA assay kit (Thermo
288 Fisher Scientific, Waltham, MA, USA) following the manufacturer's instructions. Briefly,
289 3, 7 or 14 days after AdMSCs or OBs were cultured in contact with the 52S-BG particles,
290 the cells were thoroughly washed twice with PBS. Subsequently, the cells were vigorously
291 resuspended with 500 μ L ultra-pure dH₂O (Aqua, B. Braun, Melsungen, Germany). Cell
292 lysates were obtained by cycles of freeze/thawing. For the assay, equal volumes of cell lysate
293 and Quant-iT Pico-Green working solution were pipetted into a 96-well plate. The plates
294 were incubated for 5 min at 37 °C. Thereafter, fluorescence was determined (emission: 520
295 nm and excitation: 485 nm) in the plate reader. The DNA concentrations were calculated
296 using a calibration curve.

297 2.9. ALP activity

298 ALP activity was evaluated as a first indication of osteogenic differentiation. In brief,
299 1, 3, 7 or 14 days after culture of AdMSCs or OBs with the 52S-BG particles, cells were
300 washed twice with PBS and incubated with ALP substrate solution. This solution consisted
301 of 3.4 mM pNpp (4-nitrophenyl phosphate di-sodium salt hexahydrate) prepared in a basic
302 buffer. Cells were incubated with the ALP substrate solution for 30 min at 37 °C and the
303 absorbance was determined at 405 nm using the plate reader.

304 2.10. Mineralization

305 2.10.1. AdMSCs cultured with 52S-BG particles. Analysis of matrix mineralization
306 was performed by Alizarin Red S staining. For this, AdMSCs were cultured with 100 μ g
307 ml⁻¹ or 300 μ g ml⁻¹ 52S-BG particles (Table 1). The experimental conditions used for the
308 cell culture are summarized in Table 1. At predetermined observation times of 14, 21 or 35
309 days after culture, cells were carefully washed with PBS to remove glass particles. Particular

310 care was taken to ensure complete BG particle removal to prevent their reaction with the
311 Alizarin Red S dye. Subsequently, the cells were fixed with 96% ethanol for 30 min at 4 °C,
312 washed with dH₂O and stained with 0.5% Alizarin Red S solution for 10 min at room
313 temperature. Images were obtained with the Keyence B7-9000 microscope. For
314 quantification, Alizarin Red S dye was extracted from the cell layer by adding 10%
315 hexadecylpyridiniumchloride and subsequently incubating for 15 min at room temperature.
316 The absorbance was determined at 405 nm using the plate reader.

317 2.10.2. AdMSCs cultured on PCL/52S-BG scaffolds. von Kossa staining was
318 performed 14, 21 or 35 days after AdMSC culture on PCL or PCL/52S-BG scaffolds. For
319 this, cells-seeded scaffolds were incubated in ice cold methanol (Carl Roth GmbH) for 15
320 min and thereafter in 3% silver nitrate solution (MERCK Millipore) for 30 min at room
321 temperature. Subsequently, samples were washed with dH₂O and incubated in 1%
322 pyrogallol solution (Carl Roth GmbH) for 3 min. Sample fixation was performed by
323 incubating the samples in 5% sodium thiosulfate solution (MERCK Millipore) for 5 min and
324 in 96% ethanol for 1 min. Images were obtained with the Keyence B7-9000 microscope.

325 Electron microscopy using a SEM/EDX was performed after 35 days of culture.
326 Samples were dehydrated by sequential immersion in 30%, 45%, 70%, 85% and 100%
327 ethanol solutions (2 × 15 min) followed by treatment with hexamethyldisilazane (3 × 10
328 min) and air dried overnight. In this case, a JEOL J-7100F field emission SEM (JEOL Ltd)
329 was used. The equipment was coupled to an EDX detector Inca 250 (Oxford Instruments
330 Ltd) and backscattered electron detector. The samples were analyzed using an acceleration
331 voltage of 20 kV. The samples were coated with carbon to improve their conductivity.

332 2.11. Gene expression

333 Gene expression analysis was performed to evaluate cellular events such as (i)
334 proliferation (Cyclin D1 and minichromosome maintenance complex 5 (Mcm5), (ii)
335 apoptosis (B-cell lymphoma 2 (Bcl2) and caspase 3), (iii) osteogenesis (Runt- related
336 transcription factor 2 (RunX2), ALP, osteocalcin and osteopontin), (iv) ECM secretion
337 (collagen I) and (v) vascularization (vascular endothelial growth factor (VEGF)). The
338 primers used (Eurofins, Planegg, Germany) are listed in the ESI Table S1.†

339 AdMSCs and OBs cultured with either 100 µg ml⁻¹ or 300 µg ml⁻¹ 52S-BG
340 particles were used for gene expression analysis. Cells cultured without 52S-BG particles
341 but under the same conditions were used as controls. Moreover, AdMSCs were additionally

342 cultured on the PCL/52S-BG scaffolds, using PCL scaffolds without glass content for
343 comparison. During these experiments, serum starvation medium was used as indicated in
344 Table 1.

345 At the predetermined observation times of 3, 7 or 14 days after culture, the culture
346 media was removed and the cell monolayer (52S-BG particles culture) and cell-seeded
347 scaffold were thoroughly washed with PBS. Subsequently, RNA isolation reagent (TRI
348 reagent®, MERCK Millipore) was added to each well plate (500 µL per well for the particles
349 or 150 µL per scaffold). Cell lysis was performed by a freeze/thawing cycle in TRI reagent®.
350 For cells cultured with the 52S-BG particles, the cellular material was collected using a cell
351 scraper (Sarstedt AG, Nümbrecht, Germany). For cell-seeded scaffolds, the samples were
352 briefly vortexed to ensure the collection of all cellular material. RNA isolation was
353 performed using a standard chloroform extraction protocol followed by ethanol
354 precipitation. RNA was quantified using a Biophotometer (Eppendorf AG) by determining
355 the absorbance at 280 nm. Purity was determined by the 260/280 nm and 260/230 nm ratios.
356 RNA was retro-transcribed to cDNA immediately after isolation with the first strand cDNA
357 synthesis kit (Thermo Fisher Scientific) following the manufacturer's instructions and using
358 as the thermocycler a C1000 Touch Thermal Cycler (Eppendorf AG). The obtained cDNA
359 was diluted in ultrapure, PCR grade ddH₂O (Carl Roth GmbH) to a final concentration of
360 10 ng µL⁻¹.

361 Quantification of gene expression was performed by realtime quantitative
362 polymerase chain reaction (qPCR) using 30 ng cDNA template and SsoFast EvaGreen
363 supermix (Bio-Rad Laboratories Inc., Hercules, CA, USA) in a CFX96 Real Time System
364 (Bio-Rad Laboratories Inc.). The thermal profile consisted of an initial denaturation cycle (3
365 min at 95 °C) followed by 40 cycles of short denaturation (40 s at 95 °C) and
366 annealing/extension (10 s at 60 °C).

367 For the cells cultured with 52S-BG particles, the target Ct values were subtracted
368 from the Ct values of the housekeeper (β-tubulin) to obtain the dCt values. The dCt values
369 from the control samples, that is, cells cultured without the BG particles, were subtracted
370 from the correspondent experimental groups to obtain ddCt values, which were expressed as
371 2^{-ddCt}. For the cells cultured on the scaffold, dCt values were calculated and expressed as
372 2^{-dCt}.

373 2.12. VEGF protein secretion and total protein quantification

374 The supernatants corresponding to AdMSCs cultured with either 52S-BG particles
375 or PCL/52S-BG scaffolds were collected at 3, 7 or 14 days after culture for total protein and
376 VEGF quantification. Total protein content was quantified by the Lowry assay using bovine
377 serum albumin as the standard. Briefly, samples and standards were incubated for 10 min at
378 room temperature with a solution containing 0.02% di-sodium tartrate (MERCK Millipore)
379 and 0.01% CuSO₄. This was followed by a 1.5 h incubation with 0.4 g ml⁻¹ Folin's reagent.
380 The protein concentration was calculated by determining the absorbance at 750 nm in the
381 plate reader. The amount of VEGF secreted to the cell culture media was analyzed by
382 enzyme-linked immunosorbent assay using the human VEGF Quantikine ELISA kit (R&D
383 Systems Inc., Minneapolis, MN, USA) following the manufacturer's instructions. The total
384 protein content in each sample was used to normalize the VEGF content between samples.

385 2.13. Angiogenesis induced by 52S-BG particles in vivo: zebrafish embryo model

386 To obtain the ionic dissolution products from the 52S-BG particles, 10% (w/v) of
387 particles were incubated in embryonic medium at 37 °C in an orbital shaker for 3 or 7 days.
388 Following centrifugation, the samples were filtered with a 0.2 µm cellulose acetate
389 membrane and adjusted to pH 7. The embryonic medium used in these experiments was
390 prepared from a stock salt solution (40 g Instant Ocean® Salt, Blacksburg, VA, USA) in
391 dH₂O by reverse osmosis to a final concentration of 60 µg ml⁻¹ (pH 7). The soluble Si and
392 Ca ions leached from the 52S-BG particles were determined by inductively coupled plasma
393 mass spectrometry.

394 A zebrafish (*Danio rerio*) breeding colony (wild-type AB strain) provided by N.
395 Calcaterra (IBR-CONICET, Rosario, Argentina) were maintained at the Zebrafish Facilities
396 of the National University of Salta, Argentina. Zebrafish embryos, 48 h post-fertilization
397 (hpf) and previously dechorionated and depigmented were used. Depigmentation was
398 performed at 24 hpf with 0.2 mM 1-phenyl-2-thiourea. Embryos were incubated in six-well
399 plates at 28.5 °C for 24 h. The working volume used was 5 ml per well. Study samples were:
400 plain embryonic medium (negative control), embryonic medium containing the ionic
401 dissolution products from the 52S-BG particles and embryonic medium supplemented with
402 10 µg ml⁻¹ basic fibroblast growth factor (bFGF, positive control). Thirty (n = 30) embryos
403 were used per treatment and each experiment was performed twice (n = 2). Once the
404 observation time of 24 h was reached, the embryos were anesthetized with tricaine, fixed in
405 paraformaldehyde at 4% for 1 h at room temperature and processed to subsequently analyze

406 the subintestinal vascular plexus by enzyme-histochemical identification of endogenous
407 alkaline phosphatase, following the protocol described by Kamei et al.³⁶ Images were
408 obtained using the digital microscope Keyence VHX-900F (scans) and the Keyence B7-
409 9000 fluorescent microscope (10× magnification). Semi-quantification of the sub-intestinal
410 vein (SIV) was performed using the imaging analysis software Fiji for Image J (National
411 Institutes of Health, Bethesda, MD, USA). The SIV space delimited by veins below the same
412 five somites was selected to calculate the SIV area. The length of the SIV basket was also
413 determined by considering the distance between the posterior cardinal vein and the bottom
414 end of the SIV. Additionally, the number of compartments per SIV was also calculated.

415 2.14. Statistical analysis

416 Cell culture experiments reported in this study were performed using triplicate
417 samples or more. Each experiment was independently repeated at least twice. Three different
418 human donors were used per tissue type. For the zebrafish experiments, 30 embryos per
419 group was used in two independent experiments. Therefore, 60 individual samples were
420 considered per analyzed group.

421 Statistical analysis was performed with GraphPad prism 9.0.0 (GraphPad software,
422 San Diego, CA, USA). Data was analyzed by one-way ANOVA and Tukey's correction
423 (Gaussian distribution) or Kruskal–Wallis and Dunn's correction (non- Gaussian
424 distribution). When only two data sets were compared, data was analyzed with the two-
425 tailed Student T test. Values were considered significant at $p < 0.05$. The p values were
426 reported following GraphPad recommendations (i.e. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$,
427 **** $p < 0.0001$).

428

429 3. Results

430 3.1. Physical and chemical characterization of synthesized 52S-BG

431 A new type of bioactive glass was obtained using silica sand and calcite mineral as
432 precursor materials. The obtained glass, termed 52S-BG, was rich in silica and free of P₂O₅.
433 Its chemical composition is shown in Table 2. The main oxides that form the glass were
434 SiO₂ (52.1 ± 0.3 wt%), Na₂O (23.2 ± 0.1 wt%) and CaO (22.6 ± 0.5 wt%). Other
435 elements, including Al₂O₃ and MgO, were present in small amounts and represented in total
436 ≤ 0.61 wt% of the total mass. Negligible P₂O₅ content (≤ 0.027 wt%) was detected. XRD

437 analysis showed the presence of a broad band at 32° (Fig. 1A), known to be present in
438 amorphous materials. Unexpectedly, few peaks appeared in the diffractogram, which may
439 indicate the presence of crystalline phases. This might be related to the presence of trace
440 elements within the glass that could be responsible for inducing the crystallization of some
441 silicate phases.^{22,37} Thermal analysis performed by TG-DTA showed a total mass loss of
442 <1% upon heating (Fig. 1B), which can be explained by water loss at 82 °C (α) and –OH
443 group breakage at 174 °C (β). Moreover, an endothermic transformation was observed at
444 564 °C (γ) caused by glass transition (T_g), followed by an exothermic transformation
445 between 680–690 °C (δ) caused by glass crystallization (T_c). Finally, melting occurred at
446 1282 °C (ϵ), which corresponded to glass fusion (T_m).

447 3.2. In vitro bioactivity of 52S-BG: dissolution ionic products

448 An in vitro incubation in SBF was performed to evaluate 52S-BG bioactivity. Two
449 weeks post incubation, mineral deposition could be observed on the glass surface (SEM, Fig.
450 1C). The deposited mineral layer resembled a dense apatite-like layer. At higher
451 magnification (insert in Fig. 1C), a cauliflower- like morphology of a dimension in the order
452 of few micrometers was observed. This morphology is typically observed on bioactive
453 materials as a reaction to SBF immersion. A representative EDX spectrum (Fig. 1C)
454 indicated that the mineral deposits were composed of calcium (Ca) and phosphate (P).

455 A fine 52S-BG powder was produced from the obtained glass discs by mechanical
456 milling. Over 90% of these 52S-BG particles were characterized by a size of 372.7 ± 31.2
457 nm. Incubation of these particles in cell culture media resulted in a rapid pH increase (first
458 30 min), which occurred in a concentration-dependent manner (Fig. 1D). It was noted that
459 after 3 and 7 days of incubation the pH stabilized to values of 7.6–8 for all the tested
460 conditions, comparable to that of the control (cell culture media alone). The concentration
461 of relevant ions (i.e. Si, Na, Ca and P) was analyzed after incubating different amounts of
462 52S-BG particles in cell culture media. The release curves are shown in Fig. 1E. Overall, a
463 dependency was observed between the concentration of ions released into the media and the
464 number of particles incubated. In the case of Si, this ion was detected in the range of 3–48
465 ppm and its concentration increased proportionally to the 52S-BG concentration. Most of
466 the Si release occurred during the first 24 h of incubation, indicating a burst-like release. For
467 the lower 52S-BG concentrations tested, Si peaked at approximately 24 h after incubation.
468 Increasing the 52S-BG concentration to 1000 $\mu\text{g ml}^{-1}$ resulted in a steady increase of Si

469 levels, with no peak reached up to 7 days post-incubation. Na, Ca and P release displayed
470 different patterns from Si. Na levels initially increased for all samples containing ≥ 200 μg
471 ml^{-1} . Interestingly, in the sample containing the low 52S-BG particle concentration of 100
472 $\mu\text{g ml}^{-1}$, an initial reduction of the Na concentration was observed to below that present in
473 plain cell culture medium. This indicated a Na uptake from the medium by the glass particles.
474 At the end of the observation period of 7 days, Na levels were in the range 136–295 ppm
475 when considering all the evaluated samples. Ca and P levels displayed very similar patterns
476 that were specific for each glass concentration. Interestingly, these two ions showed a
477 decrease with the incubation time. This may indicate that an uptake of Ca and P by the glass
478 particles occurred during the incubation in cell culture medium.

479 3.3. Cytotoxicity and proliferation of AdMSCs and OBs in contact with 52S-BG particles

480 The cytotoxicity of 52S-BG particles was tested in vitro using human AdMSCs and
481 OBs with a range of particle concentrations of 100–1000 $\mu\text{g ml}^{-1}$ (Fig. 2A and B). The
482 highest concentration of 1000 $\mu\text{g ml}^{-1}$ particles resulted in significant cytotoxicity for both
483 cell types at all the evaluated observation times ($p < 0.001$). Interestingly, the 52S-BG
484 particles impacted the metabolic activity of AdMSCs and OBs in a dose-dependent manner.
485 A concentration of 52S-BG particles of ≤ 400 $\mu\text{g ml}^{-1}$ resulted in high biocompatibility on
486 AdMSCs while OBs appeared to be more susceptible to cell death when exposed to a high
487 glass particle concentration. Metabolically active AdMSCs significantly increased
488 proportionally to the glass concentration ($p < 0.001$) at day 7 compared to that of days 1 and
489 3 after culture. By contrast, the metabolic activity of OBs tended to decrease with increasing
490 52S-BG particle concentration for up to 3 days (Fig. 2B). For the culture containing 400 μg
491 ml^{-1} 52S-BG particles, OB metabolic activity was approximately 70% compared to the
492 control ($p < 0.05$), indicating slight toxicity. However, after 7 days of culture, the OB
493 metabolic activity was restored to levels similar to the 100% viability control.
494 Concentrations of 200 and 300 $\mu\text{g ml}^{-1}$ 52S-BG particles resulted in a significant increase
495 in metabolically active OBs after 7 days of culture ($p < 0.05$). These results agree with the
496 live/dead staining (Fig. 2C), showing that after 7 days of culture with 52S-BG particles at
497 concentrations up to 400 $\mu\text{g ml}^{-1}$, the majority of AdMSCs and OBs were alive and
498 apoptotic cells were almost undetectable. In the 1000 $\mu\text{g ml}^{-1}$ 52S-BG particles culture
499 groups, no cells were detectable, indicating that all the cells had died and detached from the
500 plate. Interestingly, the cell organization was greatly impacted by the presence of the glass
501 particles. This was particularly observed for AdMSCs, where flower-like cellular clusters

502 were formed that were more pronounced in the presence of a higher particle concentration
503 (Fig. 2C, upper row).

504 The influence of 52S-BG particles on AdMSC and OB proliferation was also
505 evaluated. 52S-BG particles at concentrations up to 400 $\mu\text{g ml}^{-1}$ supported AdMSC
506 proliferation over time and was concentration-dependent (Fig. 2D). In particular, the
507 proliferation rate of AdMSCs cultured with 400 $\mu\text{g ml}^{-1}$ 52S-BG particles increased
508 significantly between 3 and 7 days of culture ($p < 0.05$). A similar proliferative behavior
509 was observed for OBs (Fig. 2E). In this case, however, it was noted that 400 $\mu\text{g ml}^{-1}$ 52S-
510 BG particles did not appear to stimulate OB proliferation. Indeed, OB proliferation when in
511 contact with 400 $\mu\text{g ml}^{-1}$ particles was significantly lower than that when cultured with
512 lower concentrations of 52S-BG particles ($p < 0.05$). Little or no dsDNA was detected in
513 the 1000 $\mu\text{g ml}^{-1}$ culture conditions for both AdMSCs and OBs (Fig. 2D and E).

514 3.4. Effect of 52S-BG particles on ALP activity of AdMSCs and OBs

515 To evaluate whether the newly developed glass formulation could stimulate
516 osteogenesis in vitro, we first evaluated its effect on ALP activity of both cell types. Because
517 1000 $\mu\text{g ml}^{-1}$ displayed cytotoxicity towards the cells, we excluded this con- centration in
518 further tests.

519 When cultured under serum starvation and no additional supplementation, both
520 AdMSCs and OBs displayed decreased ALP activity with increasing 52S-BG concentration
521 (Fig. 3A and C). OBs after 14 days of culture with the different glass particle concentrations
522 displayed very similar ALP activity results and no decrease of the activity values was
523 detected. In the presence of 300 $\mu\text{g ml}^{-1}$ 52S-BG particles, β -glycerophosphate and L-
524 ascorbate-2-phosphate, AdMSCs clearly displayed increased ALP activity with time (Fig.
525 3B), which was statistically significant at 14 days post-culture compared to control ($p <$
526 0.05). By contrast, ALP activity of OBs decreased with increasing 52S-BG concentration up
527 to 7 days of in vitro culture (Fig. 3D). On the basis of these results, 52S-BG particles in
528 concentrations of 100 $\mu\text{g ml}^{-1}$ and 300 $\mu\text{g ml}^{-1}$ were selected to further study the osteogenic
529 effect of this material.

530 3.5. Mineralized matrix deposition by AdMSCs in contact with 52S-BG particles

531 A positive effect on mineral deposition by AdMSCs was observed upon culturing
532 these cells with 300 $\mu\text{g ml}^{-1}$ 52S-BG particles (Fig. 3E). At 35 days post-stimulation, ample

533 mineralized matrix was observed. 52S-BG particles in culture medium without cells showed
534 no background staining (Fig. 3E, material control). Colorimetric quantification of Alizarin
535 Red S dye after extraction supported the qualitative observations (Fig. 3F). Matrix
536 mineralization was significantly higher for AdMSCs in the presence of 300 $\mu\text{g ml}^{-1}$ 52S-
537 BG particles ($p < 0.05$, 35 days). Moreover, a synergistic action was observed, where β -
538 glycerophosphate and L-ascorbate-2-phosphate appeared to be crucial for in vitro
539 mineralization induced by the 52S-BG particles. AdMSCs that were solely stimulated with
540 β -glycerophosphate and L-ascorbate-2-phosphate, that is, in the absence of 52S-BG
541 particles, did not display mineralization (Fig. 3E, upper row). SEM/EDX analysis of the
542 mineral nodules found in the 300 $\mu\text{g ml}^{-1}$ group confirmed that the deposited mineral
543 consisted of calcium and phosphate (Fig. 3G).

544 3.6. Effect of 52S-BG particles on AdMSC and OB gene expression

545 The expression of the proliferation marker Cyclin D1 was increased by both cell
546 types after 3 days of culture in the presence of 52S-BG (Fig. 4A and B). This effect was
547 particularly clear when cells were cultured with 300 $\mu\text{g ml}^{-1}$ 52S-BG particles, with both
548 cell types showing a 2-fold increase in Cyclin D1 expression, although not statistically
549 significant ($p > 0.05$). Cyclin D1 expression upregulation was supported by an upregulation
550 of Mcm5 in AdMSCs after 3 days of culture with 300 $\mu\text{g ml}^{-1}$ 52S-BG (ESI Fig. S1A[†]). Of
551 note, at the later time of observation of 14 days, a significant upregulation of 4-fold ($p <$
552 0.05) of Cyclin D1 expression was observed for OB cultures with 300 $\mu\text{g ml}^{-1}$ 52S-BG
553 (Fig. 4B). This may indicate a positive effect of the 52S-BG particles on OB proliferation.
554 However, the analysis of OB Mcm5 gene expression showed a negligible effect of the
555 particles on its expression (ESI Fig. S1B[†]).

556 With respect to apoptosis, no significant changes in the gene expression of the pro-
557 apoptotic marker Casp3 was found in either cell type or the conditions evaluated (Fig. 4A
558 and B). Furthermore, no significant effect of 52S-BG was detected on AdMSC expression
559 of the anti-apoptotic marker Bcl2 (ESI Fig. S1C[†]). Interestingly, OBs cultured for 14 days
560 with 300 $\mu\text{g ml}^{-1}$ 52S-BG particles displayed upregulated Bcl2 expression ($p > 0.05$, ESI
561 Fig. S1D[†]).

562 Subsequently, the gene expression patterns of the osteo- genic markers RunX2, ALP,
563 osteocalcin, osteopontin and collagen type I were evaluated. The results are shown in Fig.
564 4C, E and G for AdMSCs and Fig. 4D, F and H for OBs. Cell culture with 52S-BG slightly

565 stimulated the expression of the early osteogenic marker RunX2 (Fig. 4C and D). This was
566 more pronounced for OBs (Fig. 4D), which showed an upregulation of RunX2 for both 52S-
567 BG concentrations tested. An ALP upregulation was also observed for both cell types. After
568 14 days of culture with 300 $\mu\text{g ml}^{-1}$ 52S-BG, ALP was significantly upregulated ($p < 0.05$
569 for AdMSC, Fig. 4C and $p < 0.0001$ for OBs, Fig. 4D). Interestingly, the lower 52S-BG
570 particle concentration tested (i.e. 100 $\mu\text{g ml}^{-1}$) stimulated early ALP expression (7 days
571 after culture) in AdMSCs. This might indicate that concentrations $< 300 \mu\text{g ml}^{-1}$ 52S-BG
572 are required when early ALP expression is desired in AdMSCs cultures, possibly due to a
573 more efficient cellular uptake of released ions from the glass particles. The late osteogenesis
574 marker osteocalcin displayed significant upregulation only in OBs cultured with 300 μg
575 ml^{-1} 52S-BG particles (4-fold, $p < 0.01$, Fig. 4F). Notably, osteopontin expression was
576 significantly upregulated in AdMSCs (5- to 10-fold, $p < 0.05$) and OBs (10- to 30-fold, $p <$
577 0.05) with 300 $\mu\text{g ml}^{-1}$ 52S-BG particles (Fig. 4E and F). The expression pattern of
578 osteopontin with time of the in vitro culture was similar for both cell types cultured with the
579 glass particles. Collagen type I expression, as an indication of matrix deposition, was also
580 evaluated. Similar to osteocalcin, this marker displayed significant upregulation only for
581 OBs cultured with 300 $\mu\text{g ml}^{-1}$ 52S-BG particles (9-fold, $p < 0.0001$, Fig. 4H), but in this
582 case at a later time of culture.

583 3.7. Effect of 52S-BG particles on angiogenesis: gene expression and protein secretion

584 To gain an insight into the angiogenic properties of the newly developed 52S-BG,
585 VEGF expression and protein production were evaluated. AdMSC and OB cultures followed
586 a similar 52S-BG dose-dependent VEGF expression pattern. VEGF gene expression was
587 upregulated after 3 days of AdMSC (2.5-fold) and OB (6-fold, $p < 0.001$) culture with 300
588 $\mu\text{g ml}^{-1}$ 52S-BG particles (Fig. 5A). Thereafter, VEGF expression decreased to control
589 levels. However, at a later culture time (i.e. 14 days), VEGF expression slightly increased
590 again for the higher concentration of glass particles (300 $\mu\text{g ml}^{-1}$). In addition to gene
591 expression analysis, VEGF protein secretion was evaluated in AdMSCs (Fig. 5B). Cells
592 cultured in the presence of the glass displayed an overall lower protein production in
593 comparison to control cells. Despite this, VEGF production steadily increased in the presence
594 of the glass particles over time ($p = 0.0001$), while the control cells appeared to reach a
595 plateau between 7 and 14 days of culture. VEGF production by AdMSCs on 52S-BG
596 stimulation appeared to be initiated at late times after in vitro stimulation.

597 3.8. Effect of 52S-BG particles on in vivo angiogenesis

598 The subintestinal plexus or “vascular bed” of the developing fish embryo is ideal to
599 investigate the early stages of organ- specific vessel formation. It comprises the
600 suprainstestinal artery, SIV and interconnecting vessels. In our study, zebrafish embryos
601 incubated with solutions containing released glass ions (ESI Table S2†) displayed vessel
602 formation similar to that observed in the positive, growth factor control (Fig. 5D and E). By
603 contrast, a stereotypical basket-shaped structure formation was observed in the negative
604 controls (i.e. zebrafish embryo grown in standard media, Fig. 5C). The semi-quantification
605 at the SIV region for the 52S-BG-treated groups showed an increase in the SIV area similar
606 to that of the bFGF-positive control group (Fig. 5F). At 24 h post exposure, no significant
607 difference in the SIV area was found between the 7-day 52S-BG ionic dissolution product
608 group and the bFGF positive control ($p = 0.42$). Moreover, the number of compartments
609 and vascular loops formed were also greater for the 52S-BG-treated embryos when
610 compared to the negative control (Fig. 5G). Remarkably, in some individual embryos, the
611 number of vascular loops observed was even higher than in the bFGF-positive control group.
612 In terms of the SIV bud length, the 52S-BG-treated embryos displayed greater values than
613 the negative control (Fig. 5H). However, the obtained length was still significantly less than
614 the bFGF-positive stimulated embryos ($p < 0.007$).

615 3.9. PCL/52S-BG composite scaffolds: fabrication and characterization, weight loss, 616 water uptake and ion release

617 PCL scaffolds containing 10 wt% 52S-BG were successfully fabricated by additive
618 manufacturing. Macroscopically, PCL and PCL/52S-BG scaffolds had similar morphology
619 and pore shape

620 (Fig. 6A). The distribution of 52S-BG particles in the PCL matrix was homogenous
621 (Fig. 6A, glass particles shown in red). All scaffolds featured high porosity with values of
622 $\geq 76\%$. However, further investigation revealed that the incorporation of 10 wt% 52S-BG
623 particles led to increased fiber thickness as well as a minor decrease in total porosity, from
624 $80.05 \pm 3.7\%$ in PCL scaffolds to $76.56 \pm 5.98\%$, and pore size, restricted to 300–700 μm in
625 the PCL/52S-BG scaffolds (Fig. 6A and B). Interestingly, pores $>700 \mu\text{m}$ were present in
626 the plain PCL scaffolds (Fig. 6B).

627 Incorporation of 52S-BG particles increased the Young’s modulus from 180 MPa in
628 PCL scaffolds to 230 MPa in PCL/ 52S-BG scaffolds ($p < 0.0001$) when tested in dry

629 conditions (Fig. 6C). Following incubation in PBS, the Young's modulus of PCL scaffolds
630 displayed a negligible change (up to 28 days of incubation). By contrast, for PCL/52S-BG
631 scaffolds, the Young's modulus significantly decreased at 14 days post-incubation ($p <$
632 0.05).

633 The weight loss and water uptake were significantly affected by the incorporation of
634 52S-BG particles to the scaffolds. Upon PBS incubation, PCL/52S-BG scaffolds displayed
635 an approximately 10% weight loss (Fig. 6D). In addition, these scaffolds showed a water
636 uptake peak of 200% of the initial scaffold weight at 14 days post-incubation (Fig. 6E). By
637 contrast, PCL scaffolds displayed negligible weight loss and water uptake after incubation
638 in PBS. In addition, neither scaffold (PCL or PCL/52S-BG) significantly changed the pH of
639 the cell culture media, which slightly fluctuated around pH 8.6 from 3 h up to 7 days of
640 incubation (Fig. 6F).

641 Si ions were released gradually from PCL/52S-BG scaffolds, whereas no Si release
642 was detected from the PCL scaffolds (Fig. 6G). Na increased for both scaffolds during the
643 first 24 h post-incubation, with no differences in Na release when comparing the PCL and
644 PCL/52S-BG scaffolds. P and Ca concentrations were in the same range for both scaffolds
645 and followed similar tendencies to remain unchanged for all the observation times ($p > 0.05$).

646 3.10. Biocompatibility and cytotoxicity of PCL/52S-BG scaffolds to AdMSCs

647 PCL/52S-BG scaffolds induced significantly less LDH release by AdMSCs
648 compared to the PCL scaffolds (Fig. 7A, $p < 0.05$ at 7 days). In agreement with this, the
649 composite scaffolds also displayed a significant increase of attached, metabolically active
650 cells from 3 days of culture onwards (Fig. 7B). Indeed, at 7 days post-culture, a significantly
651 higher metabolic activity was detected for the cells seeded on the composite scaffolds ($p <$
652 0.01 , Fig. 7B). These results were supported by live/dead staining of 7-day cultures (Fig.
653 7C). In addition, seeding efficiency was increased from 11.88% in PCL to 24.41% in
654 PCL/52S-BG scaffolds, indicating that the 52S-BG particles improved cell attachment (Fig.
655 7D).

656 3.11. Effect of PCL/52S-BG scaffolds on AdMSC gene and protein expression

657 Gene expression was evaluated after culture of AdMSCs on PCL and PCL/52S-BG
658 scaffolds. No significant differences were observed between PCL and PCL/52S-BG in terms
659 of the proliferation marker Cyclin D1 or the apoptosis marker Casp3 (Fig. 7E and F). RunX2

660 expression appeared to be higher in the PCL/52S-BG scaffolds compared to PCL, although
661 this was not statistically significant (Fig. 7G). Similar results were observed for ALP
662 expression at 7 days post-culture (Fig. 7H). No significant difference was observed in
663 osteocalcin expression between the two scaffolds (Fig. 7I). By contrast, osteopontin,
664 displayed an upregulation in AdMSCs cultured on PCL/52S-BG scaffolds already at 3 days
665 post-culture ($p < 0.05$, Fig. 7J). This early upregulation of osteopontin expression agrees
666 with the results obtained using 52S-BG particles with both, AdMSCs and OBs.
667 Unexpectedly, collagen I expression was downregulated in AdMSCs cultured on PCL/52S-
668 BG scaffolds ($p < 0.05$ at 14 days, Fig. 7K). Notably, at days 3 and 7 after AdMSC culture
669 on PCL/52S-BG scaffolds, VEGF gene expression and protein secretion were significantly
670 upregulated compared to PCL scaffolds ($p < 0.05$, Fig. 7L and M).

671 3.12. Mineralized matrix formation by AdMSCs on PCL/ 52S-BG scaffolds

672 Abundant mineral deposition was observed on PCL/52S-BG scaffolds at days 21 and
673 35 after AdMSC culture (Fig. 8A). By contrast, negligible mineral deposits were observed
674 on PCL scaffolds (Fig. 8A). At 35 days after in vitro culture on PCL/ 52S-BG scaffolds, the
675 surface of the scaffolds appeared entirely covered by a mineral layer which extended
676 between the pores. SEM observations confirmed the mineral layer deposits on PCL/52S-BG
677 scaffolds (Fig. 8B, right panels). In addition, cells could be identified growing inside the
678 cauliflower-like mineral formation. EDX analysis confirmed the presence of calcium
679 phosphate deposits on the surface of the PCL/52S-BG scaffolds (Fig. 8C).

680

681 4. Discussion

682 In this study, a new phosphate-free, silicate-based BG was synthesized and
683 characterized. Synthesis was performed by the conventional melt quenching method. This
684 procedure, although resulting in glasses of less porosity than the ones obtained via sol-gel,
685 is considerably less expensive.²² In addition, melt quenched glasses exhibit the advantage
686 of superior mechanical properties,³⁸ a highly desired feature for materials used in bone
687 engineering applications.

688 The obtained glass material appears to be biocompatible with human primary cells,
689 capable of inducing in vitro mineralization and, remarkably, in vitro and in vivo
690 angiogenesis. A concentration-dependent effect was demonstrated in our study.

691 BGs are well-known to cause a pH rise when immersed in aqueous solutions.³⁹
692 According to Hench,⁴⁰ this initial pH spike is an indicator of ion exchange between modifier
693 cations from the BG and protons from the dissolution medium followed by alkaline
694 hydrolysis of Si–O–Si bonds and subsequent formation of silanol (Si–OH) groups.
695 Consequently, the dis- solution medium becomes depleted of protons and the pH increases.
696 After just 30 min of immersion in SBF, the pH of the dissolution media increased linearly
697 with increasing 52S-BG particle concentration. However, no significant difference was
698 observed in the Na or Ca concentrations (modifier cations) in all 52S-BG particle groups
699 compared to the control. This is most likely due to the late observation time-point (6 hours
700 after immersion), because the pH spike was observed as early as 30 min after incubation. By
701 contrast, at $>200 \mu\text{g ml}^{-1}$ 52S-BG particles, significantly higher Si was observed compared
702 to the control, indicating that a pH increase to a certain threshold is necessary to disrupt the
703 Si–O–Si glass network.³⁹ The in vitro bioactivity of 52S-BG was confirmed by the presence
704 of calcium phosphate deposits on the glass surface after incubation with SBF.

705 Cell culture studies showed that 52S-BG particles at a con- centration $<400 \mu\text{g ml}^{-1}$
706 can support AdMSC and OB growth and proliferation. However, a high 52S-BG
707 concentration ($1000 \mu\text{g ml}^{-1}$) was cytotoxic to both cell types, most likely because of the
708 rise in the culture media pH and the presence of high concentrations of glass dissolution
709 ionic products. It has been reported that high Si⁴¹ and cytosolic Ca⁴² levels can trigger
710 downstream events that induce cell apoptosis. Similar cytotoxicity effects of BGs have been

711 previously reported⁴³⁻⁴⁵ and may be avoided by pre-conditioning the BGs prior to cell
712 culture.^{44,45}

713 Overall, it was observed that AdMSCs and OBs were differentially regulated by 52S-
714 BG. This may be related to the ions released from the 52S-BG particles. To further elucidate
715 this, the gene expression of cell cycle regulators and osteogenic markers was analyzed. Bcl-
716 2 is a growth-promoting, antiapoptotic effector while Cyclin D1 promotes cell cycle entry
717 by inducing the G1/S transition. In OBs exposed to 300 $\mu\text{g ml}^{-1}$ 52S-BG particles, the time-
718 point of highest Bcl-2 expression coincided with that of Cyclin D1. Xynos et al.⁴⁶ also
719 observed Cyclin D1 upregulation in OBs after 48 h of culture with 45S5 Bioglass® extracts.
720 In agreement with these findings, Sun et al.⁴⁷ and Xynos et al.⁴⁸ demonstrated that the ionic
721 products of 45S5 Bioglass® induced OB proliferation by accelerating the growth cycle
722 through G1/S, resulting in a more rapid G2 entry. Collectively, these results provide new
723 insights into the molecular mechanisms by which BGs affect OB growth and proliferation,
724 which appear to involve Cyclin D1 and Bcl2 but not the cell cycle effector Mcm5, a DNA
725 helicase downstream of Cyclin D1. For AdMSCs, however, it appears that the regulation of
726 cell growth and proliferation may involve other molecules, which need to be further
727 elucidated in future studies.

728 AdMSCs and OBs displayed the highest osteogenic potential when exposed to 300
729 $\mu\text{g ml}^{-1}$ 52S-BG particles. This indicated that 52S-BG dissolution products were able to
730 induce osteogenesis in these cells. Of note, 52S-BG appeared to act synergistically with β -
731 glycerophosphate and L-ascorbate-2-phosphate to further enhance osteogenesis. This agrees
732 with previous observations by Poh et al. who presented two distinctive PCL/BG composite
733 scaffolds with enhanced osteopontin and osteocalcin expression in the presence of β -
734 glycerophosphate and L-ascorbate-2-phosphate supplements.⁴⁵

735 Although BGs are well-known for their bioactivity and osteo- genic potential, wider
736 clinical implementation in orthopedic applications is frequently impeded by their brittleness.
737 Leveraging on the additive manufacturing capability, PCL/ 52S-BG composite scaffolds
738 were fabricated to harness the bioactivity of 52S-BG while improving the biomaterial bulk
739 mechanical properties. In comparison to PCL scaffolds, PCL/

740 52S-BG composite scaffolds featured thicker microfilaments and smaller pore size,
741 resulting in an approximately 5% decrease in total porosity. During the scaffold fabrication

742 process, the extrusion temperature for the composite was slightly higher than for PCL,
743 causing a delayed solidification and resulting in microfilament sagging and increased
744 filament size.¹⁹ Although there were small changes in the scaffold morphology, the porosity
745 and pore size remained within the optimal range for bone tissue engineering applications
746 (100–500 μm pores¹ and 50–90% porosity⁴⁹). The homogenous incorporation of 10 wt%
747 52S-BG particles into the PCL bulk improved the compressive Young's modulus of
748 PCL/52S-BG scaffolds compared to PCL scaffolds. The increased microfilament thickness
749 and reduced porosity in PCL/52S-BG scaffolds could also contribute to the enhanced
750 PCL/52S-BG scaffolds' compressive Young's modulus. These results are in agreement with
751 the those obtained by Poh et al.,^{19,26} Korpela et al.⁵⁰ and Jiang et al.,⁵¹ who incorporated
752 various types of BGs or hydroxy- apatite particles into PCL. After 14 or 28 days in PBS, the
753 com- pressive Young's modulus of the PCL/52S-BG scaffolds decreased most probably
754 because of the dissolution of 52S-BG particles coupled with insufficient glass–polymer
755 interaction. Modifying the PCL or BG to increase their interfacial bonding may help to
756 improve the scaffolds' mechanical properties under physiological conditions.⁵² Although
757 the Young's modulus of the fabricated PCL/52S-BG scaffolds remains significantly lower
758 than that of native bone tissue (0.05–0.5 GPa in trabecular bone and 7–30 GPa in cortical
759 bone¹), we have shown that increased stiffness compared to PCL scaffolds improved
760 mechanical resistance and could promote osteogenic differentiation in vitro, consistent with
761 the findings of other studies.^{53,54}

762 We found that AdMSC attachment, proliferation, osteogenic differentiation and
763 mineralized matrix formation were significantly enhanced in PCL/52S-BG composite
764 scaffolds compared to PCL scaffolds. This may be attributed to several factors. Water uptake
765 into PCL/52S-BG scaffolds significantly increased after 7 days of incubation in PBS
766 compared to PCL scaffolds, indicating improved hydrophilicity and thereby better support
767 of cell attachment.^{55,56} Secondly, the dissolution ionic products from 52S-BG particles
768 embedded within the PCL bulk may have contributed towards the improved osteogenic
769 differentiation of AdMSCs. The occurrence of physical–chemical reactions (e.g.
770 crystallization of Ca–P on scaffold surfaces) enables the inter- action of collagen molecules
771 with the scaffold surface and triggers cascades of events favoring AdMSC adhesion,
772 proliferation, differentiation and matrix deposition.⁵⁷ In addition, 52S-BG incorporation
773 may lead to an increase in surface roughness, which is favorable for cell attachment and
774 proliferation.^{43,58}

775 Not surprisingly, osteogenic RunX2 and osteopontin expression appeared to be better
776 supported by the PCL/52S-BG composite scaffold than by the 52S-BG particles alone. This
777 may be related to the 3D structure and topography of the scaffolds. It has been reported that
778 scaffold topography and stiffness can significantly affect gene expression.⁵⁹ Another
779 important difference was regarding the ion release. Overall, ions were released from the
780 composite scaffolds over a long time period. Si, for example, was released slower and more
781 progressively from PCL/52S-BG scaffolds when compared to the glass particles suspension.
782 In this regard, it is well-documented that ionic dissolution products of BGs, such as Si and Ca,
783 are capable of inducing osteogenesis in vitro (reviewed in ref. 3).

784 The success rate of bone regeneration and remodeling is highly dependent on the
785 extent of vascularization, particularly for critical-sized bone defects.⁶⁰ Therefore,
786 angiogenesis is a much-desired feature in bone substitute materials. We found that 52S-BG
787 particles upregulated VEGF expression in AdMSCs and OBs as early as 3 days after culture.
788 Interestingly, a second but lower bout was observed. We did not find similar evidence in
789 current bioactive glass literature. We speculate that this second VEGF upregulation might
790 be due to the agglomeration formed between the cells and the BG particles at later times
791 after culture. The originated cell-particle mass may have created relative hypoxia
792 responsible for this second VEGF increase observed at 14 days post-stimulation.

793 Strikingly, these particles were also able to induce vessel formation in vivo in a
794 zebrafish embryo to a similar extent as bFGF. This evidence supports a robust angiogenic
795 potential of these new glass particles, which was retained after the composite scaffold
796 fabrication. PCL/52S-BG composite scaffolds promoted VEGF protein release by AdMSCs.
797 This angiogenic characteristic may also be associated with ion release from the 52S-BG
798 particles. It was proposed by Zhai et al.⁶¹ that Si plays a major role in the induction of blood
799 vessel formation. In an elegantly presented review article, Kargozar et al. described the
800 angiogenic potential of silicate-based BGs.¹¹ Our glass, being rich in Si (52 wt%), may thus
801 be provided with superior angiogenic properties. Overall, the data presented here suggest
802 that neither P2O5 groups nor metallic dopants may be needed in 52S-BG to be angiogenic
803 while retaining its osteogenic features. Further investigations should focus on in-depth ion
804 release and degradation, in particular given that this material contains trace elements that
805 conferred minimal crystallinity. In vivo testing using a relevant bone defect model should
806 also be considered to confirm osteogenic and angiogenic properties.

807

808 **5. Conclusions**

809 The BG presented in this paper, that is 52S-BG may be of interest for clinical
810 application based on its combined osteogenic and angiogenic properties. Furthermore, the
811 possibility of combining 52S-BG with polymers to obtain a 3D composite scaffold may be
812 highly relevant for the repair of large bone seg- mental defects. In vivo studies in, for
813 example, small animal fracture models may be relevant to unravel the translational potential
814 of this novel material.

815

816 **Author contributions**

817 Conceptualization: E.R.B. Formal analysis: S.F.T., S.P.P.P., M. v. G., E.R.B.
818 Funding acquisition: A.G., M.v. G., E.R.B. Investigation: S.F.T., J.A.D., S.P.P.P., W.Z.,
819 M.G.-V., L.M. Project administration: M. v. G., E.R.B. Resources: S.M., A.G., M.v.G.
820 Supervision: E.R.B. Visualization: S.F.T., E.R.B. Writing (original draft): S.F.T., E.R.B.
821 Writing (review & editing): all authors.

822

823

824

825

826 **Conflicts of Interest**

827 There are no conflicts to declare.

828

829 **Acknowledgements**

830 This study was partially funded by the Zeidler Foundation (Grant ID: Regentesis).
831 The authors acknowledge the support received from BAYLAT – CONICET for the
832 collaborative work between the universities in Bavaria, Germany and Salta, Argentina.

833

834

835

836 **References**

- 837 1 L.-C. Gerhardt and A. R. Boccaccini, *Materials*, 2010, 3, 3867.
- 838 2 L. L. Hench, R. J. Splinter, W. C. Allen and T. K. Greenlee, *J. Biomed. Mater. Res.*,
839 1971, 5, 117–141.
- 840 3 A. Hoppe, N. S. Guldal and A. R. Boccaccini, *Biomaterials*, 2011, 32, 2757–2774.
- 841 4 X. Zhou, N. Zhang, S. Mankoci and N. Sahai, *J. Biomed. Mater. Res., Part A*, 2017,
842 105, 2090–2102.
- 843 5 M. Julien, S. Khoshniat, A. Lacreusette, M. Gatius, A. Bozec, E. F. Wagner, Y.
844 Wittrant, M. Masson, P. Weiss, L. Beck, D. Magne and J. Guicheux, *J. Bone Miner.
845 Res.*, 2009, 24, 1856–1868.
- 846 6 B. Cabal, L. Alou, F. Cafini, R. Couceiro, D. Sevillano, L. Esteban-Tejeda, F. Guitian,
847 R. Torrecillas and J. S. Moya, *Sci. Rep.*, 2014, 4, 5440.
- 848 7 J. R. Jones, O. Tsigkou, E. E. Coates, M. M. Stevens, J. M. Polak and L. L. Hench,
849 *Biomaterials*, 2007, 28, 1653–1663.
- 850 8 M. Suarez, E. Fernandez-Garcia, A. Fernandez, R. Lopez- Piriz, R. Diaz and R.
851 Torrecillas, *Sci. Rep.*, 2020, 10, 13171.
- 852 9 J. R. Jones and L. L. Hench, *J. Biomed. Mater. Res., Part B*, 2004, 68, 36–44.
- 853 10 D. Lukito, J. M. Xue and J. Wang, *Mater. Lett.*, 2005, 59, 3267–3271.
- 854 11 S. Kargozar, F. Baino, S. Hamzehlou, R. G. Hill and M. Mozafari, *Trends Biotechnol.*,
855 2018, 36, 430–444.
- 856 12 G. Bühner, U. Rottensteiner, A. Hoppe, R. Detsch, D. Dafinova, T. Fey, P. Greil, C.
857 Weis, J. P. Beier, A. R. Boccacini, R. E. Horch and A. Arkudas, *Biomed. Glas.*, 2016,
858 2, 111–117.
- 859 13 S. Kargozar, N. Lotfibakhshaiesh, J. Ai, M. Mozafari, P. Brouki Milan, S. Hamzehlou,
860 M. Barati, F. Baino, R. G. Hill and M. T. Joghataei, *Acta Biomater.*, 2017, 58, 502–
861 514.
- 862 14 L. A. Haro Durand, G. E. Vargas, N. M. Romero, R. Vera- Mesones, J. M. Porto-
863 Lopez, A. R. Boccaccini, M. P. Zago,

- 864 A. Baldi and A. Gorustovich, *J. Mater. Chem. B*, 2015, 3, 1142–1148.
- 865 15 A. Hoppe, A. Brandl, O. Bleiziffer, A. Arkudas, R. E. Horch, B. Jokic, D. Janackovic
866 and A. R. Boccaccini, *Mater. Sci. Eng., C*, 2015, 57, 157–163.
- 867 16 E. Littmann, H. Autefage, A. K. Solanki, C. Kallepitis, J. R. Jones, M. Alini, M.
868 Peroglio and M. M. Stevens, *J. Eur. Ceram. Soc.*, 2018, 38, 877–886.
- 869 17 M. N. Rahaman, W. Xiao and W. Huang, *Biomed. Glas.*, 2017, 3, 56–66.
- 870 18 L. L. Hench and J. R. Jones, *Front. Bioeng. Biotechnol.*, 2015, 3, 194.
- 871 19 P. S. Poh, D. W. Hutmacher, M. M. Stevens and M. A. Woodruff, *Biofabrication*,
872 2013, 5, 045005.
- 873 20 E. R. Balmayor, I. Pashkuleva, A. M. Frias, H. S. Azevedo and R. L. Reis, *J. R. Soc.,
874 Interface*, 2011, 8, 896–908.
- 875 21 D. Mondal, M. Griffith and S. S. Venkatraman, *Int. J. Polym. Mater.*, 2016, 65, 255–
876 265.
- 877 22 L. Morejón, J. A. Delgado, M. García-Vallés, S. Martínez, E. R. Balmayor and M. van
878 Griensven, *Int. J. Mater. Res.*, 2019, 110, 333–342.
- 879 23 T. Kokubo, H. Kushitani, S. Sakka, T. Kitsugi and T. Yamamuro, *J. Biomed. Mater.
880 Res.*, 1990, 24, 721–734.
- 881 24 A. Liu, Z. Hong, X. Zhuang, X. Chen, Y. Cui, Y. Liu and X. Jing, *Acta Biomater.*,
882 2008, 4, 1005–1015.
- 883 25 S. K. Misra, D. Mohn, T. J. Brunner, W. J. Stark, S. E. Philip, I. Roy, V. Salih, J. C.
884 Knowles and A. R. Boccaccini, *Biomaterials*, 2008, 29, 1750–1761.
- 885 26 P. S. P. Poh, D. W. Hutmacher, B. M. Holzapfel, A. K. Solanki, M. M. Stevens and
886 M. A. Woodruff, *Acta Biomater.*, 2016, 30, 319–333.
- 887 27 G. A. Silva, F. J. Costa, N. M. Neves, O. P. Coutinho, A.C. Dias and R. L. Reis, *J.
888 Biomed. Mater. Res., Part A*, 2005, 73, 234–243.
- 889 28 S. Schneider, M. Unger, M. van Griensven and E. R. Balmayor, *Eur. J.
890 Med. Res.*, 2017, 22, 17.
- 891 29 S. Payr, E. Rosado-Balmayor, T. Tiefenboeck, T. Schuseil, M. Unger, C. Seeliger and

- 892 M. van Griensven, *J. Orthop. Surg. Res.*, 2021, 16, 13.
- 893 30 R. R. Pochampally, J. R. Smith, J. Ylostalo and D. J. Prockop, *Blood*, 2004, 103, 1647–
894 1652.
- 895 31 A. Oskowitz, H. McFerrin, M. Gutschow, M. L. Carter and R. Pochampally, *Stem Cell*
896 *Res.*, 2011, 6, 215–225.
- 897 32 B. Y. Binder, J. E. Sagun and J. K. Leach, *Stem Cell Rev. Rep.*, 2015, 11, 387–393.
- 898 33 F. Langenbach and J. Handschel, *Stem Cell Res. Ther.*, 2013, 4, 117.
- 899 34 E. R. Balmayor, T. E. Baran, M. Unger, A. P. Marques, H. S. Azevedo and R. L. Reis,
900 *J. Biomed. Mater. Res., Part B*, 2015, 103, 1610–1620.
- 901 35 F. K. Chan, K. Moriwaki and M. J. De Rosa, *Methods Mol. Biol.*, 2013, 979, 65–70.
- 902 36 M. Kamei, S. Isogai, W. Pan and B. M. Weinstein, *Methods Cell Biol.*, 2010, 100, 27–
903 54.
- 904 37 E. A. De Maeyer and R. M. Verbeeck, *J. Biomed. Mater. Res.*, 2001, 57, 467–472.
- 905 38 G. Kaur, G. Pickrell, N. Sriranganathan, V. Kumar and D. Homa, *J. Biomed. Mater.*
906 *Res., Part B*, 2016, 104, 1248–1275.
- 907 39 D. S. Brauer, *Angew. Chem., Int. Ed.*, 2015, 54, 4160–4181.
- 908 40 L. L. Hench, *J. Am. Ceram. Soc.*, 1991, 74, 1487–1510.
- 909 41 S. I. Anderson, PhD, Nottingham, 2001, <http://eprints.nottingham.ac.uk/13541/>.
- 910 42 C. S. Adams, K. Mansfield, R. L. Perlot and I. M. Shapiro, *J. Biol. Chem.*, 2001, 276,
911 20316–20322.
- 912 43 J. Rodenas-Rochina, J. L. Ribelles and M. Lebourg, *J. Mater. Sci. Mater. Med.*, 2013,
913 24, 1293–1308.
- 914 44 S. Midha, T. B. Kim, W. van den Bergh, P. D. Lee, J. R. Jones and C. A. Mitchell,
915 *Acta Biomater.*, 2013, 9, 9169–9182.
- 916 45 P. S. Poh, D. W. Hutmacher, B. M. Holzapfel, A. K. Solanki, M. M. Stevens and M.
917 A. Woodruff, *Acta Biomater.*, 2016, 30, 319–333.
- 918 46 I. D. Xynos, A. J. Edgar, L. D. Buttery, L. L. Hench and J. M. Polak, *J. Biomed. Mater.*

919 Res., 2001, 55, 151–157.

920 47 J. Y. Sun, Y. S. Yang, J. Zhong and D. C. Greenspan, *J. Tissue Eng. Regener. Med.*,
921 2007, 1, 281–286.

922 48 I. D. Xynos, A. J. Edgar, L. D. Buttery, L. L. Hench and J. M. Polak, *Biochem.*
923 *Biophys. Res. Commun.*, 2000, 276, 461–465.

924 49 J. Y. Kim and D.-W. Cho, *Microsyst. Technol.*, 2009, 15, 843–851.

925 50 J. Korpela, A. Kokkari, H. Korhonen, M. Malin, T. Narhi and J. Seppala, *J. Biomed.*
926 *Mater. Res., Part B*, 2013, 101, 610–619.

927 51 W. Jiang, J. Shi, W. Li and K. Sun, *J. Biomater. Sci., Polym. Ed.*, 2013, 24, 539–550.

928 52 A. J. Harmata, C. L. Ward, K. J. Zienkiewicz, J. C. Wenke and S. A. Guelcher, *J.*
929 *Mater. Res.*, 2014, 29, 2398–2407.

930 53 C. Yang, M. W. Tibbitt, L. Basta and K. S. Anseth, *Nat. Mater.*, 2014, 13, 645–652.

931 54 A. J. Engler, S. Sen, H. L. Sweeney and D. E. Discher, *Cell*, 2006, 126, 677–689.

932 55 M. Hafezi, S. Safarian, M. T. Khorasani and N. A. Abu Osman, *RSC Adv.*, 2016, 6,
933 35815–35824.

934 56 B. Lei, K. H. Shin, D. Y. Noh, Y. H. Koh, W. Y. Choi and H. E. Kim, *J. Biomed.*
935 *Mater. Res., Part B*, 2012, 100, 967–975.

936 57 A. E. Clark, L. L. Hench and H. A. Paschall, *J. Biomed. Mater. Res.*, 1976, 10, 161–
937 174.

938 58 W. Yang, W. Han, W. He, J. Li, J. Wang, H. Feng and Y. Qian, *Mater. Sci. Eng., C*,
939 2016, 60, 45–53.

940 59 R. A. Perez and G. Mestres, *Mater. Sci. Eng., C*, 2016, 61, 922–939.

941 60 J. Henkel, M. A. Woodruff, D. R. Epari, R. Steck, V. Glatt, I. C. Dickinson, P. F.
942 Choong, M. A. Schuetz and D. W. Huttmacher, *Bone Res.*, 2013, 1, 216–248.

943 61 W. Zhai, H. Lu, L. Chen, X. Lin, Y. Huang, K. Dai, K. Naoki, G. Chen and J. Chang,
944 *Acta Biomater.*, 2012, 8, 341–349.

945

946

947 **Table 1.** Experimental setup: in vitro cell culture and in vivo angiogenesis

948

52S-BG particles					
Assay	Cell type		Zebrafish embryo	Type of culture media	52S-BG concentration ($\mu\text{g ml}^{-1}$)
	AdMSCs	OBs			
Live/dead staining	✓	✓	—	Expansion	100, 200, 300, 400, 1000
Cytotoxicity (MTT)	✓	✓	—	Expansion	
Cell proliferation (PicoGreen)	✓	✓	—	Expansion	
ALP activity	✓	✓	—	Serum starvation ($\pm\beta\text{GlyP}$ and AA)	100, 200, 300, 400
Matrix mineralization (Alizarin RedS)	✓	—	—	Serum starvation ($\pm\beta\text{GlyP}$ and AA)	100 and 300
Gene expression (qPCR)	✓	✓	—	Serum starvation ($\pm\beta\text{GlyP}$ and AA)	100 and 300
VEGF protein (ELISA)	✓	—	—	Serum starvation ($+\beta\text{GlyP}$ and AA)	300
Angiogenesis (functional assay)	—	—	✓	Embryonic medium	100

PCL and PCL/52S-BG scaffolds		
Assay	Cell type: AdMSCs	Type of culture media
Live/dead staining	✓	Expansion
Cytotoxicity (MTT and LDH)	✓	Expansion
Matrix mineralization (von Kossa)	✓	Serum starvation ($+\beta\text{GlyP}$ and AA)
Gene expression (qPCR)	✓	Serum starvation ($+\beta\text{GlyP}$ and AA)
VEGF protein (ELISA)	✓	Serum starvation ($+\beta\text{GlyP}$ and AA)

949

950 Abbreviations: βGlyP = β -glycerophosphate, AA = L-Ascorbate-2-phosphate, human
 951 AdMSCs = human adiposederived mesenchymal stromal cells, human OBs = human
 952 osteoblasts, MTT = 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, ALP =
 953 alkaline phosphatase, qPCR = real- time quantitative polymerase chain reaction, VEGF =
 954 vascular endothelial growth factor, ELISA = enzyme-linked immunosorbent assay, LDH =
 955 lactate dehydrogenase, PCL = poly- ϵ -caprolactone.

956

957

958 **Table 2.** Composition of obtained 52S-BG as determined by X-ray fluorescence, mean \pm
959 standard deviation (SD). Of note, the 52S-BG was obtained using natural origin precursors,
960 that is silica sand and calcite minerals. This fact may explain the presence of diverse trace
961 elements found in the glass

962

Oxide	SiO ₂	Na ₂ O	CaO	Al ₂ O ₃	MgO	TiO ₂	Fe ₂ O ₃	P ₂ O ₅	K ₂ O
wt% \pm SD	52.1 \pm 0.3	23.2 \pm 0.1	22.6 \pm 0.5	0.26 \pm 0.04	0.16 \pm 0.01	0.06 \pm 0.005	0.032 \pm 0.003	0.024 \pm 0.003	0.011 \pm 0.002

963

964

965

966

967 Figures Captions

968 **Figure. 1.** Characterization of 52S-BG particles, in vitro bioactivity and ion release. (A)
969 Representative XRD spectrum of the 52S-BG discs, (B) TG-DTA curve showing 52S-BG
970 weight and energy release with increasing temperature, (C) in vitro bioactivity analysis of
971 52S-BG discs by SEM (left) and EDX (right) showing mineral deposition on the glass
972 surface after 15 days of incubation in SBF and (D) pH of DMEM medium on incubation
973 with 0–1000 $\mu\text{g ml}^{-1}$ 52S-BG particles ($n = 6$, mean \pm SEM). (E) Cumulative release of Si,
974 Na, Ca and P ions from 52S-BG particles (0–1000 $\mu\text{g ml}^{-1}$). The ion release was
975 investigated in DMEM medium without further supplementation. The data were normalized
976 to the DMEM ionic concentration ($n = 3$, mean \pm SEM).

977 **Figure. 2.** In vitro biocompatibility of 52S-BG particles evaluated on human adipose-
978 derived mesenchymal stem cells (AdMSCs) and osteoblasts (OBs). Metabolic activity of (A)
979 AdMSCs and (B) OBs after 1, 3 or 7 days of culture in the presence of 100–1000 $\mu\text{g ml}^{-1}$
980 52S-BG particles. Dashed line indicates 100% viable cells (i.e. cells cultured in medium
981 without glass particles). Results are reported as mean \pm SEM. (C) Calcein AM/PI/Hoechst
982 staining of AdMSCs and OBs after 7 days of culture with 52S-BG particles (100–1000 μg
983 ml^{-1}) showing viable cells (green), apoptotic cells (red) and cell nuclei (blue). Cell
984 proliferation of (D) AdMSCs and (E) OBs cultured in the presence of 100–400 $\mu\text{g ml}^{-1}$
985 52S-BG particles. Results are expressed as $\text{ng } \mu\text{l}^{-1}$ of dsDNA and reported as the mean \pm
986 SEM. * $p < 0.05$, *** $p < 0.001$, **** $p < 0.0001$

987 **Figure. 3.** ALP activity and mineralization of human adipose-derived mesenchymal stem
988 cells (AdMSCs) and human osteoblasts (OBs) after exposure to various 52S-BG particle
989 concentrations. ALP activity in (A) and (B) AdMSCs and (C) and (D) OBs cultured with
990 100, 200, 300 or 400 $\mu\text{g ml}^{-1}$ 52S-BG particles. The effect of adding β -glycerophosphate
991 (β GlyP) and L-ascorbate-2-phosphate (AA) is shown. ALP results are expressed as fold
992 change to control samples (mean \pm SEM). Cell cultures without 52S-BG particles were used
993 as a control (dashed line). (E) Alizarin Red S staining of AdMSCs cul- tured for 14, 21 or
994 35 days in presence of 100 or 300 $\mu\text{g ml}^{-1}$ 52S-BG particles. 52S-BG particles incubated in
995 cell culture medium was used as a material control. Scale bars = 600 μm . (F) Alizarin Red
996 S quantification reported as mg ml^{-1} of hexadecylpyridiniumchloride (mean \pm SEM).
997 Statistical significance is indicated by * $p < 0.05$. (G) SEM image (left) and EDX semi-
998 quantification of mineral deposits (right) observed on the AdMSC extra- cellular matrix
999 when exposed to 300 $\mu\text{g ml}^{-1}$ 52S-BG particles.

1000 **Figure. 4.** Gene expression analysis of proliferation, apoptosis and osteogenesis in human
1001 adipose-derived mesenchymal stem cells (AdMSCs) and human osteoblasts (OBs) exposed
1002 to 100 or 300 $\mu\text{g ml}^{-1}$ 52S-BG particles. (A) and (B) Proliferation- and apoptosis-related
1003 markers, Cyclin D1 and Casp3, respectively. (C)–(H) Osteogenesis-related markers, RunX2,
1004 ALP, osteocalcin, osteopontin and collagen I. The effect of adding β -glycerophosphate
1005 (β GlyP) and L-ascorbate-2-phosphate (AA) is shown. Gene expression is expressed as fold
1006 change (mean \pm SEM) of ddCt values ($2^{-\text{ddCt}}$) with respect to the control sample (dashed
1007 line). * $p < 0.05$, ** $p < 0.01$, **** $p < 0.0001$.

1008 **Figure. 5.** In vitro and in vivo angiogenic properties of the 52S-BG particles. (A) VEGF
1009 gene expression in human adipose-derived mesenchymal stem cells (AdMSCs) and human
1010 osteoblasts (OBs) after culture in the presence of 100 or 300 $\mu\text{g ml}^{-1}$ 52S-BG particles for

1011 3, 7 or 14 days. The effect of adding β -glycerophosphate (β GlyP) and L-ascorbate-2-
1012 phosphate (AA) is shown. Results are expressed as fold change (mean \pm SEM) of ddCt
1013 values (2^{-ddCt}) with respect to the control sample (dashed line). *** $p < 0.001$. (B) VEGF
1014 production by AdMSCs at 3, 7 and 14 days after stimulation with $300 \mu\text{g ml}^{-1}$ 52S-BG
1015 particles. Results are expressed as pg VEGF normalized to the total protein content (mean \pm
1016 SEM). ** $p < 0.01$. (C)–(E) Subintestinal vascular plexus of zebrafish embryos 72 hpf (side
1017 view) at 24 h post-stimulation with the ionic dissolution products from the 52S-BG particles.
1018 The sub-intestinal vein (SIV) used for semi-quantification purposes is shown within the
1019 dashed squares. Representative images are shown for negative control, 52S-BG particles and
1020 positive bFGF control. Scale bars = $500 \mu\text{m}$. Results of the Fiji quantification are presented
1021 as a boxplot with whiskers from minimum to maximum: (F) SIV area, (G) number of
1022 compartments per SIV and (H) length of the SIV basket. * $p < 0.05$ and *** $p < 0.001$. $n =$
1023 60 individual zebrafish embryos were analyzed per group.

1024 **Figure. 6.** Characterization of PCL/52S-BG composite scaffolds. (A) 3D μ CT reconstruction
1025 image showing the microstructure of the obtained PCL (left side; side and frontal views) and
1026 PCL/52S-BG (right side) scaffolds. Red dots, indicating embedded 52S-BG particles,
1027 illustrate the distribution of the glass within the PCL matrix (white). Total and open porosity
1028 percentage are reported in a table below the images. (B) Filament thickness and pore size of
1029 the obtained PCL and PCL/52S-BG scaffolds as calculated by μ CT ($n = 6$; mean \pm SEM).
1030 (C) Mechanical characterization of PCL and PCL/ 52S-BG scaffolds shown by the Young's
1031 modulus (mean \pm SEM, MPa). Scaffolds were tested before ($t = 0$ days) and after ($t = 14$ or
1032 28 days) of immersion in PBS. Also depicted are the stress–strain curves obtained for PCL
1033 and PCL/52S-BG scaffolds before ($t = 0$ days) immersion in PBS. $n = 8$ scaffolds per group
1034 were used for the mechanical analysis. (D) Weight loss and (E) water uptake of PCL and
1035 PCL/52S-BG scaffolds upon 28 days of incubation in PBS. Results are expressed as the
1036 percentage of either weight loss or weight gain ($n = 8$; mean \pm SEM). (F) pH variation of
1037 low glucose DMEM as a result of incubation of PCL or PCL/52S-BG scaffolds for up to 7
1038 days ($n = 3$; mean \pm SEM). (G) Cumulative release of Si, Na, Ca and P ions from PCL and
1039 PCL/52S-BG scaffolds upon incubation in low glucose DMEM for up to 7 days. The data
1040 were normalized to the DMEM ionic concentration ($n = 3$; mean \pm SEM). * $p < 0.05$, ** p
1041 < 0.01 , *** $p < 0.001$, **** $p < 0.0001$.


1042 **Figure. 7.** Biocompatibility and gene expression of AdMSCs cultured on PCL/52S-BG
1043 composite scaffolds. (A) LDH release, (B) metabolic activity (MTT test) and (C) calcein
1044 AM/PI staining analysis performed for AdMSCs cultured on PCL or PCL/52S-BG scaffolds
1045 for up to 7 days. Fluorescence microscopy images show viable cells in green and apoptotic
1046 cells in red. (D) Seeding efficiency of AdMSCs on PCL and PCL/52S-BG scaffolds. The
1047 results are expressed as the percentage of cells attached to the scaffold surface at 24 h after
1048 seeding with respect to the total cell population. (E)–(L) Gene expression of the proliferation
1049 and apoptosis markers Cyclin D1 and Casp3, respectively, as well as the osteogenic markers
1050 RunX2, ALP, osteocalcin, osteopontin and collagen I and the angiogenic marker VEGF.
1051 Gene expression is reported as fold change of dCt values (2^{-dCt}) with respect to the
1052 housekeeping gene β -tubulin. (M) VEGF production by AdMSCs cultured on PCL or
1053 PCL/52S-BG composite scaffolds. VEGF protein quantification in the cell supernatant was
1054 normalized to the total protein content (mean \pm SEM). * $p < 0.05$, *** $p < 0.001$, $n = 3$
1055 scaffolds used for analysis.

1056 **Figure 8.** Mineralization of AdMSCs cultured on PCL/52S-BG composite scaffolds. (A)
1057 von Kossa staining of AdMSCs cultured on PCL and PCL/ 52S-BG scaffolds for 21 or 35
1058 days. Matrix deposits can be identified occluding the pores of the PCL/52S-BG composite
1059 scaffolds. (B) SEM images of the AdMSC-seeded scaffolds after 35 days of in vitro culture.
1060 Higher magnification images at the bottom of the figure show cells adhered to the scaffold
1061 surface as well as cellular matrix deposition. (C) EDX semi-quantification of mineral
1062 deposits found on the surface of PCL/52S-BG scaffolds.

1063

1064 **Figure 1**

1065



1066


1067

1068

1069

1070 **Figure 2**

1071



1072


1073

1074

1075

1076 **Figure 3**

1077



1078

1079


1080

1081

1082

1083 **Figure 4**

1084



1085

1086

1087


1088

1089

1090

1091 **Figure 5**


1092



1093

1094 **Figure 6**

1095



1096

1097

1098


1099

1100

1101

1102 **Figure 7**

1103



1104

1105


1106

1107

1108

1109 **Figure 8**

1110



C

Formula	Na ₂ O	MgO	SiO ₂	P ₂ O ₅	CaO
% Compound	2.07	2.22	1.72	47.69	46.3

1111

1112

1113

1114